Cargando…
Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics
The recent advent of immune checkpoint inhibitor (CPI) antibodies has revolutionized many aspects of cancer therapy, but the efficacy of these breakthrough therapeutics remains limited, as many patients fail to respond for reasons that still largely evade understanding. An array of studies in human...
Autores principales: | Buss, Colin G., Bhatia, Sangeeta N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306768/ https://www.ncbi.nlm.nih.gov/pubmed/32493746 http://dx.doi.org/10.1073/pnas.2001569117 |
Ejemplares similares
-
Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation
por: Sun, Yating, et al.
Publicado: (2017) -
Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy
por: Zhuang, Jia, et al.
Publicado: (2019) -
Nanoparticle Delivery of Immunostimulatory Alu RNA for Cancer Immunotherapy
por: Garland, Kyle M., et al.
Publicado: (2023) -
Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
por: Hu, Zishuo Ian, et al.
Publicado: (2022) -
Lipid Nanoparticle-Mediated Lymphatic Delivery of Immunostimulatory Nucleic Acids
por: Kim, Dongyoon, et al.
Publicado: (2021)